文献速递炎症性肠病

综述文章:肠道微生物群如何反映炎症性肠病疾病活动度并影响治疗结局

Review article: how the intestinal microbiota may reflect disease activity and influence therapeutic outcome in inflammatory bowel disease.
PubMed 文献 · Aliment Pharmacol Ther · 2020-09-24

该综述通过PubMed检索描述炎症性肠病(IBD)肠道微生物群与疾病严重程度及治疗结局的文献。严重IBD微生物多样性较低、共生菌群较少、机会致病菌较多;基线微生物多样性较高者对抗肿瘤坏死因子-α、维得利珠单抗和乌司奴单抗治疗应答更好。基于微生物群、临床数据和血清学标志物的预测模型对治疗结局和疾病严重程度具有良好准确性。

要点

  • 严重IBD患者肠道微生物多样性较低,共生菌群较少,机会致病菌较多。
  • 基线微生物多样性较高与抗肿瘤坏死因子-α、维得利珠单抗和乌司奴单抗治疗应答更好相关。
  • 基于微生物群、临床数据和血清学标志物的预测模型对治疗结局和疾病严重程度有良好准确性。

核心结论

  • IBD肠道微生物群携带一组有前景的疾病活动度和治疗结局预测生物标志物。
  • 当前认识可能有助于设计微生物群调节策略以改善IBD结局。

研究设计与样本

  • 描述性综述,使用PubMed检索IBD肠道微生物群相关文献。

主要发现

  • 严重IBD微生物多样性较低,共生微生物群落较少,源自口腔或呼吸道的机会致病菌较多。
  • IBD治疗可改变肠道微生物群组成,但需体外/体内研究证明因果关系。
  • 缓解期观察到微生物群多样化。
  • 基线微生物组更多样且微生物多样性更高的患者对抗肿瘤坏死因子-α、维得利珠单抗和乌司奴单抗治疗应答更好。
  • 产短链脂肪酸细菌丰度较高、黏液定植细菌较少和促炎细菌丰度较低也与良好结局相关。

关键数值与推荐

  • 基于微生物群、临床数据和血清学标志物组合的预测模型对治疗结局和疾病严重程度具有良好准确性。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intestinal bacteria produce metabolites and by-products necessary for homeostasis. Imbalance in this equilibrium is linked to multiple pathologies including inflammatory bowel disease (IBD). The role of the gut microbiota in determining treatment response is becoming apparent, and may act as biomarker for efficacy. AIM: To describe knowledge about the intestinal microbiota on disease severity and treatment outcomes in IBD METHODS: Descriptive review using PubMed to identify literature on the intestinal microbiota in IBD RESULTS: Severe IBD has a less diverse microbiota with fewer commensal microbiota communities and more opportunistic pathogenic bacteria originating from the oral cavity or respiratory tract. IBD treatments can alter gut microbiota composition, but in vitro/in vivo studies are needed to prove causation. A diversification of the microbiota is observed during remission. Patients with a more diverse baseline microbiome and higher microbial diversity show better response to anti-tumour necrosis factor-α, vedolizumab and ustekinumab therapy. Higher abundance of short chain fatty acid-producing bacteria, fewer mucus-colonising bacteria and lower abundance of pro-inflammatory bacteria have also been associated with a favourable outcome. Predictive models, based on a combination of microbiota, clinical data and serological markers, have good accuracy for treatment outcome and disease severity. CONCLUSION: The intestinal microbiota in IBD carries a set of promising biomarkers of disease activity and prediction of therapeutic outcome. Current insights may also help in designing microbiota modulation strategies to improve outcomes in IBD.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Caenepeel C, Sadat Seyed Tabib N, Vieira-Silva S, et al. Review article: how the intestinal microbiota may reflect disease activity and influence therapeutic outcome in inflammatory bowel disease. Aliment Pharmacol Ther. 2020. PMID: 32969507. doi:10.1111/apt.16096

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。